Profund Advisors LLC Has $1.95 Million Stake in GRAIL, Inc. $GRAL

Profund Advisors LLC lifted its holdings in shares of GRAIL, Inc. (NASDAQ:GRAL) by 141.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 22,776 shares of the company’s stock after acquiring an additional 13,334 shares during the quarter. Profund Advisors LLC owned approximately 0.06% of GRAIL worth $1,949,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in GRAL. N.E.W. Advisory Services LLC acquired a new stake in GRAIL during the 4th quarter valued at $26,000. Elyxium Wealth LLC acquired a new position in shares of GRAIL in the fourth quarter valued at $31,000. Comerica Bank increased its holdings in shares of GRAIL by 59.2% in the third quarter. Comerica Bank now owns 465 shares of the company’s stock valued at $27,000 after purchasing an additional 173 shares during the last quarter. Allworth Financial LP raised its position in shares of GRAIL by 47.3% in the fourth quarter. Allworth Financial LP now owns 894 shares of the company’s stock valued at $77,000 after purchasing an additional 287 shares during the period. Finally, Rossby Financial LCC bought a new position in shares of GRAIL in the third quarter valued at about $62,000.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GRAIL in a report on Tuesday, April 21st. Canaccord Genuity Group lowered their price target on shares of GRAIL from $105.00 to $80.00 and set a “buy” rating on the stock in a report on Friday, February 20th. TD Cowen raised their price objective on shares of GRAIL from $65.00 to $69.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Morgan Stanley reduced their price objective on GRAIL from $110.00 to $60.00 and set an “equal weight” rating for the company in a report on Tuesday, February 24th. Finally, Guggenheim decreased their target price on GRAIL from $130.00 to $75.00 and set a “buy” rating on the stock in a research report on Monday, March 30th. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, GRAIL presently has an average rating of “Hold” and a consensus target price of $67.88.

Insider Activity at GRAIL

In other news, CFO Aaron Freidin sold 45,806 shares of the company’s stock in a transaction on Wednesday, April 8th. The stock was sold at an average price of $49.92, for a total transaction of $2,286,635.52. Following the completion of the sale, the chief financial officer directly owned 260,669 shares in the company, valued at approximately $13,012,596.48. This represents a 14.95% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Robert P. Ragusa sold 123,502 shares of the stock in a transaction on Wednesday, April 8th. The stock was sold at an average price of $49.92, for a total value of $6,165,219.84. Following the sale, the chief executive officer directly owned 518,582 shares in the company, valued at approximately $25,887,613.44. This trade represents a 19.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 310,267 shares of company stock worth $15,485,396. Company insiders own 1.83% of the company’s stock.

GRAIL Stock Performance

GRAL stock opened at $66.03 on Thursday. The company’s 50-day simple moving average is $52.65 and its 200 day simple moving average is $76.88. GRAIL, Inc. has a 52 week low of $29.95 and a 52 week high of $118.84. The company has a market capitalization of $2.83 billion, a PE ratio of -6.37 and a beta of 3.03.

GRAIL (NASDAQ:GRAL) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($2.29) earnings per share for the quarter, topping the consensus estimate of ($2.76) by $0.47. GRAIL had a negative net margin of 253.22% and a negative return on equity of 16.42%. The business had revenue of $40.79 million during the quarter, compared to analysts’ expectations of $39.16 million. On average, analysts forecast that GRAIL, Inc. will post -10.91 EPS for the current year.

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.